VRDN – viridian therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]
Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $29.00. They now have an "equal weight" rating on the stock.
Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) [Seeking Alpha]
Viridian Therapeutics (NASDAQ:VRDN) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Form 4 Viridian Therapeutics, For: Dec 31 Filed by: Tousignant Jennifer
Form 144 Viridian Therapeutics, Filed by: Tousignant Jennifer
Form SCHEDULE 13G/A Viridian Therapeutics, Filed by: Commodore Capital LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.